Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Varela, J. E.
Right arrow Articles by Spalding, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varela, J. E.
Right arrow Articles by Spalding, P. B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 337-342
© 2000 The British Society for Antimicrobial Chemotherapy

Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries

J. Esteban Varela, Stephen M. Cohn*, Margaret Brown, C. Gillon Ward, Nicholas Namias and Paul B. Spalding

Department of Surgery, Divisions of Trauma, Burns and Surgical Critical Care, University of Miami School of Medicine, PO Box 016960 (D-40) Miami, FL 33101, USA

Adequate penetration of antibiotics into burn tissue and maintenance of effective serum levels are essential for the treatment of patients sustaining major thermal injuries. The pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin were determined in 12 critically ill patients with burn injuries. Mean age for the 12 patients was 45 ± 17 (range 25–82 years), total body surface area burned (TBSAB) = 38 ± 15% and Acute Physiology and Chronic Health Evaluation (APACHE) II score = 8 ± 6. Patients received recommended doses of ciprofloxacin, 400 mg q12h iv, for three doses beginning 72 h post-burn. Serum concentrations were measured at t = 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0, 4.0 and 12.0 h after the first and third doses. Burn eschar biopsies were obtained after the third ciprofloxacin dose. Three of these 12 patients (25%) manifested later signs of clinical sepsis (TBSAB = 61 ± 6% and APACHE II score = 11 ± 3) and underwent a second infusion of three doses of intravenous ciprofloxacin, blood sampling and eschar biopsy. Serum and eschar concentrations were determined by high performance liquid chromatography. Serum ciprofloxacin concentrations were comparable to those of normal volunteers (Cmax = 4.0 ± 1 mg/L and AUC = 11.4 ± 2 mg.h/L) during the immediate post-burn period after dose 1 (Cmax1 = 4.8 ± 3 mg/L and AUC0–12 = 12.5 ± 7 mg.h/L) and dose 3 (Cmax3 = 4.9 ± 2 mg/L and AUC24–36 = 17.5 ± 11 mg.h/L). Mean burn eschar concentration during the 72 h post-burn was significantly lower than that found during clinical sepsis (18 ± 17 compared with 41.3 ± 54 µg/g; P < 0.05 by t test). Similar serum concentrations were achieved in patients with clinical sepsis (Cmax1 = 4.2 ± 0.2 mg/L and AUC0–12 = 15.0 ± 3 mg.h/L; Cmax3 = 5.0 ± 1 mg/L and AUC24–36 = 22.8 ± 9 mg.h/L). A positive correlation between burn eschar concentrations and Cmax (r = 0.71, r2 = 0.51, P = 0.01) was found by linear regression analysis. A Cmax/MIC ratio > 10 (MIC = 0.5 mg/L) and an AUC/MIC ratio > 100 SIT–1.h (serum inhibitory titre) (MIC = 0.125 mg/L) were achieved. High burn eschar concentrations and serum levels, similar to those found in normal volunteers, can be achieved after intravenous ciprofloxacin infusion in critically ill burns patients.

* Corresponding author. Tel: +1-305-585-1185; Fax: +1-305-326-7065; E-mail: stephen.cohn{at}miami.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
T. Han, J. S. Harmatz, D. J. Greenblatt, and J. A. J. Martyn
Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns
J. Clin. Pharmacol., June 1, 2007; 47(6): 674 - 680.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. M. Cook
Pharmacokinetic Alterations of Antimicrobials in the Critically Ill
Journal of Pharmacy Practice, April 1, 2005; 18(2): 75 - 83.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.